Related Experiment Video
Updated: Jun 11, 2025

Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
Health Benefits In 2024: Higher Premiums Persist, Employer Strategies For GLP-1 Coverage And Family-Building Benefits
Gary Claxton1, Matthew Rae2, Anthony Damico3
1Gary Claxton, KFF, Washington, D.C.
Employer-sponsored health coverage costs continue to rise, with family premiums increasing 7% in 2024. Deductibles also climbed, while some large employers began covering weight-loss drugs like GLP-1 antagonists.
Area of Science:
- Health Economics
- Healthcare Policy
- Employee Benefits
Background:
- Employer-sponsored health insurance is a primary source of coverage for many workers.
- Rising healthcare costs and benefit utilization present ongoing challenges for employers and employees.
Purpose of the Study:
- To analyze current trends in employer-sponsored health coverage costs, deductibles, and benefit offerings.
- To examine the impact of inflation and wage growth on health insurance premiums.
Main Methods:
- Analysis of national survey data on employer-sponsored health plans.
- Calculation of average premiums, deductibles, and worker contributions.
- Examination of trends over the past five and ten years.
Main Results:
- The average annual premium for employer-sponsored family health coverage reached $25,572 in 2024, a 7% increase from 2023.
- Family premiums have risen 24% over five years, mirroring inflation and wage growth.
- Average single-coverage deductibles increased 47% over the past decade.
- In 2024, 18% of large firms offered GLP-1 antagonists for weight loss, with 28% of very large firms providing this benefit.
Conclusions:
- Health insurance costs continue to escalate, placing a significant financial burden on both employers and employees.
- Deductibles have substantially increased, potentially impacting access to care.
- Emerging treatments like GLP-1 antagonists are beginning to be covered by some large employers, indicating a shift in benefit strategies.
More Related Videos
06:34Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices
Published on: November 29, 2024
09:31Sustained Administration of β-cell Mitogens to Intact Mouse Islets Ex Vivo Using Biodegradable Poly(lactic-co-glycolic acid) Microspheres
Published on: November 5, 2016
Related Concept Videos
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
Issues And Trends In Healthcare Delivery System
Cost Containment
Payment for healthcare services has historically promoted adoption of costly and often unnecessary or inefficient...
Dipeptidyl Peptidase 4 Inhibitors
Standards of Care II
Oral Hypoglycemic Agents: Biguanides and Glitazones
Lifestyle Factors and Health
Benefits of Physical Activity
Physical activity, whether through structured exercise or casual activities like walking, biking, or dancing, is a cornerstone of a...